FY2025 EPS Estimates for TSE:MDP Raised by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Leede Financial raised their FY2025 EPS estimates for Medexus Pharmaceuticals in a research report issued on Wednesday, January 22nd. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.29 per share for the year, up from their previous forecast of $0.20. Leede Financial currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

MDP has been the topic of a number of other reports. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Stifel Nicolaus boosted their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research note on Wednesday, January 8th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Stock Up 19.0 %

Shares of TSE:MDP opened at C$4.75 on Thursday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The company has a 50-day moving average price of C$3.14 and a 200 day moving average price of C$2.69. The company has a market cap of C$116.52 million, a P/E ratio of 95.00 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.